陆舜：临床医生在生物样本库建设中应起主导作用
Personalized medicine may be defined as “a medical model using molecular profiling technologies for tailoring the right therapeutic strategy for the right person at the right time, and determine the predisposition to disease at the population level and to deliver timely and stratified prevention”. Progress in the understanding of driven genes and drug actions are opening opportunities to match therapies to lung cancer patient populations, and thus pave the way towards a more personalized medicine. The use of driven genes such as EGFR, ALK, and ROS1 et al can help identify patients that are more likely to respond favorably to a given therapy which is approved by clinical trials. Increasingly, we find application in order to stratify different patient groups in terms of clinical response, so as to develop personalized, preventive or therapeutic strategies.
陆舜：精准肿瘤学时代基于组织标本的肺癌临床研究
Personalized medicine may be defined as “a medical model using molecular profiling technologies for tailoring the right therapeutic strategy for the right person at the right time, and determine the predisposition to disease at the population level and to deliver timely and stratified prevention”. Progress in the understanding of driven genes and drug actions are opening opportunities to match therapies to lung cancer patient populations, and thus pave the way towards a more personalized medicine. The use of driven genes such as EGFR, ALK, and ROS1 et al can help identify patients that are more likely to respond favorably to a given therapy which is approved by clinical trials. Increasingly, we find application in order to stratify different patient groups in terms of clinical response, so as to develop personalized, preventive or therapeutic strategies.
陆舜：二代测序技术在肺癌中的应用
肺癌驱动基因的研究起步很早，1987 年，找到了第一个肺癌驱动基因--Ras 突变，但是一直没有针对这个基因的药物。2004 年，两个独立研究小组找到的EGFR 突变，是第二个被发现的肺癌驱动基因，并且我们发现EGFRTKI 都表现出对其较好的抑制效果，从这个时候开启了针对肺癌驱动基因的靶向治疗。
2007 年，我们又知道了ALK也是一个肺癌驱动基因，而且针对这个基因研发的药物也取得了很好的效果。2009年以后，由于检测技术优化后，人类发现的肺癌驱动基因有30 个左右，其中包括：EGFR、ALK、KRAS、Her2、PIK3CA、ROS1、MET、BRAF 等等。
目前新一代测序技术(NGS) 已经用于肺鳞癌、腺癌、小细胞肺癌的检测，揭示基因变异高检出率可以指导肺癌的靶向治疗，已经显示良好的前景，真正开启肺癌的个体化治疗。
陆舜：肺癌个体化治疗进展
陆舜：上海交通大学附属胸科医院，主任医师，博士研究生导师。
近年来，基于肺癌发病机制的深入认识以及癌基因组学的研究成果，肺癌靶向治疗取得了突破性进展。非小细胞肺癌的治疗已经由“化疗”时代高速进入了以靶向治疗为主要手段的综合性“个体化治疗“时代。根据分子标志筛选特定的疾病人群，应用阻断此标志的化合物来抑制肿瘤生长已成为治疗肺癌的新思路。
目前已知的具有显著分子特征的标志有表皮生长因子受体（EGFR）突变、间变性淋巴瘤激酶（ALK）突变和ROS1突变等。